Reply by Authors
J Urol
.
2021 Jul;206(1):61.
doi: 10.1097/JU.0000000000001698.02.
Epub 2021 Apr 15.
Authors
Kenneth J Pienta
1
,
Michael A Gorin
1
2
,
Steven P Rowe
2
,
Peter R Carroll
3
,
Frédéric Pouliot
4
,
Stephan Probst
5
,
Lawrence Saperstein
6
,
Mark A Preston
7
,
Ajjai S Alva
8
,
Akash Patnaik
9
,
Jeremy C Durack
10
,
Nancy Stambler
11
,
Tess Lin
11
,
Jessica Jensen
11
,
Vivien Wong
11
,
Barry A Siegel
12
,
Michael J Morris
10
13
Affiliations
1
The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
2
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
3
University of California San Francisco, San Francisco, California.
4
CHU de Quebec and Laval University, Quebec City, Quebec.
5
Jewish General Hospital, Montreal, Quebec.
6
Yale School of Medicine, New Haven, Connecticut.
7
Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
8
University of Michigan, Ann Arbor, Michigan.
9
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
10
Memorial Sloan Kettering Cancer Center, New York, New York.
11
Progenics Pharmaceuticals, Inc., New York, New York.
12
Mallinckrodt Institute of Radiology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
13
Weill Cornell Medicine, New York, New York.
PMID:
33853358
DOI:
10.1097/JU.0000000000001698.02
No abstract available
Publication types
Comment